Cargando…
Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Raltegravir readily crosses the placenta to the fetus with maternal use during pregnancy. After birth, neonatal raltegravir elimination is highly variable and often extremely prolonged, with some neonates demonstrating rising profiles after birth despite removal from the source of extrinsic raltegra...
Autores principales: | Lommerse, Jos, Clarke, Diana, Kerbusch, Thomas, Merdjan, Henri, Witjes, Han, Teppler, Hedy, Mirochnick, Mark, Acosta, Edward P., Wenning, Larissa, Nachman, Sharon, Chain, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765695/ https://www.ncbi.nlm.nih.gov/pubmed/31215170 http://dx.doi.org/10.1002/psp4.12443 |
Ejemplares similares
-
Long-Term Safety from the Raltegravir Clinical Development Program
por: Teppler, Hedy, et al.
Publicado: (2011) -
A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
por: Mills, Alexander, et al.
Publicado: (2021) -
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013) -
1617 Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
por: Teppler, Hedy, et al.
Publicado: (2014) -
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)